| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LYPLAL1 |
| Uniprot No | Q5VWZ2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-237aa |
| 活性数据 | MAAASGSVLQRCIVSPAGRHSASLIFLHGSGDSGQGLRMWIKQVLNQDLTFQHIKIIYPTAPPRSYTPMKGGISNVWFDRFKITNDCPEHLESIDVMCQVLTDLIDEEVKSGIKKNRILIGGFSMGGCMAMHLAYRNHQDVAGVFALSSFLNKASAVYQALQKSNGVLPELFQCHGTADELVLHSWAEETNSMLKSLGVTTKFHSFPNVYHELSKTELDILKLWILTKLPGEMEKQK |
| 分子量 | 52.7 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人LYPLAL1蛋白的3条参考文献示例(注：部分内容基于已有研究的合理推测，实际文献可能需要进一步验证)：
---
1. **"Characterization of Recombinant Human LYPLAL1 as a Lipolytic Enzyme in Adipocytes"**
**作者**: Cousin, S.P., et al.
**摘要**: 该研究通过在大肠杆菌中重组表达LYPLAL1蛋白，证实其具有水解甘油三酯的活性，并可能通过调节脂质代谢影响脂肪细胞的脂解过程。实验表明，LYPLAL1在肥胖模型中的表达水平与脂肪分布异常相关。
2. **"Structural Insights into the Catalytic Mechanism of LYPLAL1 through Recombinant Protein Crystallography"**
**作者**: Eydoux, C., et al.
**摘要**: 通过重组LYPLAL1蛋白的纯化和结晶，解析了其三维结构，揭示了其活性位点的关键氨基酸残基及催化机制。研究发现，LYPLAL1属于丝氨酸水解酶家族，与脂肪代谢密切相关的酰基转移酶活性相关。
3. **"Functional Analysis of LYPLAL1 in Lipid Droplet Dynamics Using Recombinant Protein Overexpression"**
**作者**: Soni, K.G., et al.
**摘要**: 利用重组LYPLAL1蛋白在细胞模型中的过表达，证明其能够促进脂肪细胞中脂滴的分解，并通过AMPK信号通路调控能量代谢。研究为LYPLAL1在代谢综合征中的潜在治疗作用提供了依据。
---
**注意**：上述文献名称及内容为示例性假设，真实文献需通过学术数据库(如PubMed、Google Scholar)以关键词“recombinant LYPLAL1”、“LYPLAL1 protein function”等检索确认。
Recombinant human LYPLAL1 (Lysophospholipase-like 1) protein is a genetically engineered version of the naturally occurring enzyme encoded by the LYPLAL1 gene. Belonging to the α/β-hydrolase superfamily, LYPLAL1 shares structural homology with lysophospholipases and thioesterases, featuring a conserved catalytic triad (Ser-Asp-His) that suggests hydrolytic activity, though its precise substrates remain under investigation. Genome-wide association studies (GWAS) have linked LYPLAL1 variants to fat distribution patterns, obesity-related traits, and metabolic disorders, including type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), highlighting its potential role in lipid metabolism and energy homeostasis. However, its molecular mechanisms remain unclear, with conflicting evidence on whether it acts as a lipase, acyltransferase, or regulatory protein. Recombinant LYPLAL1 is typically expressed in bacterial or mammalian systems to enable functional studies. Researchers employ it to analyze enzymatic activity, protein interactions, and its influence on adipocyte differentiation or insulin signaling pathways. Its recombinant form also aids in structural studies, such as crystallography, to map active sites and design inhibitors. While therapeutic applications are speculative, understanding LYPLAL1’s function could illuminate obesity-related pathways and inform drug development. Current challenges include reconciling its in vitro biochemical properties with in vivo physiological roles, necessitating further mechanistic and translational studies.
×
